SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ethgen O, Kahler KH, Kong SX, Reginster JY, Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol 2002; 29: 114755.
  • 2
    Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000; 3: 24352.
  • 3
    Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005; 32: 187583.
  • 4
    Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 Suppl 31: S714.
  • 5
    Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004; 22 Suppl 1: 112.
  • 6
    Burton W, Morrison A, Raclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006; 56: 1827.
  • 7
    Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology (Oxford) 2008; 47: 18893.
  • 8
    Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006; 44: 30410.
  • 9
    Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987; 30: 50712.
  • 10
    Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 16815.
  • 11
    Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al, for the FIN-RACo Trial Group. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50: 5562.
  • 12
    Yelin E. The earnings, income, and assets of persons aged 51-61 with and without musculoskeletal conditions. J Rheumatol 1997; 24: 202430.
  • 13
    Allaire S, Wolfe F, Niu J, LaValley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum 2008; 59: 47480.
  • 14
    Backman CL, Kennedy SM, Chalmers A, Singer J. Participation in paid and unpaid work by adults with rheumatoid arthritis. J Rheumatol 2004; 31: 4757.
  • 15
    Backman CL, del Fabro Smith L, Smith S, Montie PL, Suto M. Experiences of mothers living with inflammatory arthritis. Arthritis Rheum 2007; 57: 3818.
  • 16
    Allaire SH, Meenan RF, Anderson JJ. The impact of rheumatoid arthritis on the household work performance of women. Arthritis Rheum 1991; 34: 66978.
  • 17
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 2637.
  • 18
    Klareskog L, van der Heijde DM, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 67581.
  • 19
    St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 343243.
  • 20
    Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008; 35: 20615.
  • 21
    Van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008; 67: 126770.
  • 22
    Odegard S, Landewe R, van der Heijde DM, Kvien TK, Mowinckel P, Uhlig T. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 2006; 54: 6875.
  • 23
    Kavanaugh A, Han C, Bala M. Functional status and radiographic damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 84955.
  • 24
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 25
    Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al, and the Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 146774.
  • 26
    Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 172936.
  • 27
    Lacaille D. Arthritis and employment research: where are we? Where do we need to go? J Rheumatol Suppl 2005; 72: 425.
  • 28
    Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008; 67: 34843.
  • 29
    Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 70210.
  • 30
    Han C, Smolen J, Kavanaugh A, St Clair EW. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Res Ther 2008; 59: 5104.
  • 31
    Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 3641.
  • 32
    Allaire S, Wolfe F, Niu J, LaValley M, Michaud K. Work disability and its economic effect on 55–64-year-old adults with rheumatoid arthritis. Arthritis Rheum 2005; 53: 6038.
  • 33
    Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001; 28: 171822.
  • 34
    Callahan LF, Bloch DA, Pincus T. Identification of work disability in rheumatoid arthritis: physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables. J Clin Epidemiol 1992; 45: 12738.
  • 35
    Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002; 61: 33540.
  • 36
    Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006; 33: 22549.
  • 37
    Van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 2006; 55: 56974.